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A Cost Analysis of the 1-2-3 Pap Intervention
Abstract
Background: Cervical cancer places a substantial economic burden on our healthcare system. The threedose human papillomavirus (HPV) vaccine series is a cost-effective intervention to prevent HPV infection
and resultant cervical cancer. Despite its efficacy, completion rates are low in young women aged 18
through 26 years. 1-2-3 Pap is a video intervention tested and proven to increase HPV vaccination
completion rates.
Purpose: To provide the full scope of available evidence for 1-2-3 Pap, this study adds economic evidence
to the intervention’s efficacy. This study tested the economies of scale hypothesis that the cost of 1-2-3
Pap intervention per number of completed HPV vaccine series would decrease when offered to more
women in the target population.
Methods: Using cost and efficacy data from the Rural Cancer Prevention Center, a cost analysis was done
through a hypothetical adaptation scenario in rural Kentucky.
Results: Assuming the same success rate as in the efficacy study, the 1-2-3 Pap adaptation scenario
would cover 1000 additional women aged 18 through 26 years (344 in efficacy study; 1346 in adaptation
scenario), and almost three times as many completed series (130 in efficacy study; 412 in adaptation
scenario) as in the original 1-2-3 Pap efficacy study.
Implications: Determination of the costs of implementing 1-2-3 Pap is vital for program expansion. This
study provides practitioners and decision makers with objective measures for scalability.
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C

ervical cancer, 91% of which is attributable to human papillomavirus (HPV), places a
substantial economic burden on our healthcare system.1,2 Estimated direct medical care costs
for HPV-associated diseases (e.g., cervical cancer screening and treatment) are $8 billion
annually (2010 USD).1 The three-dose HPV vaccine series through age 26 years is a cost-effective
intervention to prevent HPV infection and resultant cervical cancer.3 Despite its effectiveness,
completion rates are low in women aged 18 through 26 years, especially for those living in
underserved areas such as Appalachian Kentucky.4,5 Improving HPV vaccine completion rates,
defined as the rate of receiving the third dose, is important and women aged 18 through 26 years are
an identified target population.4,5 1-2-3 Pap is a video-based intervention created and tested by the
Rural Cancer Prevention Center (RCPC) to increase HPV vaccination completion rates among
women aged 18 through 26 years, residing in the eight-county Kentucky River Area Development
District (KRADD) who already received the first dose.5
Determining the cost of implementing 1-2-3 Pap is vital for program expansion. This study tested
the economies-of-scale hypothesis that the cost of 1-2-3 Pap intervention per number of completed
HPV vaccine series would decrease when offered to more women in the KRADD.
METHODS
The 1-2-3 Pap efficacy study, which has been described elsewhere,5 was composed of 344 women
who received the first dose of the HPV vaccine series (initiation dose). Results showed that women
who watched the video were 2.44 more likely to complete the HPV vaccine series than those who
did not.5
To test the intervention’s scalability, a cost analysis was conducted using expenditure reports from
the RCPC. Subsequently, cost changes were assessed for 1-2-3 Pap through a hypothetical
adaptation scenario within the KRADD. Institutional review board approval was not needed
because data were obtained from federal reporting documents used to monitor the Centers for
Disease Control Prevention Research Centers program. Costs included in the study were for
resources used to recruit the original 1-2-3 Pap efficacy study participants, to create and disseminate
the video, and to administer HPV vaccine doses.
The adaptation scenario sample size was estimated by multiplying the number of women aged 18
through 26 years in the KRADD (N = 5930; 2010 U.S. Decennial Census) with the national HPV
vaccination initiation rate (22.7%).4 This resulted in an estimated 1346 women who would watch the
video when receiving the first dose. During the efficacy study, the adherence (Dose 2) and
completion (Dose 3) rates among those who watched the 1-2-3 Pap video were 61.2% and 43.3%,
respectively.5 Specific adherence and completion rates for rural Kentucky are not available.
Therefore, for the adaptation scenario, the national adherence and completion rates were used for
women aged 18 through 26 years (17.6% and 12.7%, respectively).4 Assuming that the intervention
is as effective in the adaptation scenario as it was in the efficacy study, the adherence (43.6%) and
completion (30.6%) rate differences between the 1-2-3 Pap efficacy study and the national rates were
used to estimate the adaptation scenario uptake rates.4,5
Perspectives. Costs were estimated from a provider perspective, which includes only the direct
costs.
Time Frame and Analytic Horizon. A 28-month time frame and analytic horizon were assumed,
which was the length of the 1-2-3 Pap efficacy study (September 2010–December 2012).5
Direct Costs. Direct costs included 1-2-3 Pap efficacy study participant incentives, video creation
and dissemination, and clinical costs associated with administering HPV vaccine doses. The video
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creation costs included script development, studio time, editing, production services, and local talent
fees for six actors.5 The intervention was disseminated via laptop computers and administered by a
community health nurse who conducted participant intake interviews during the 1-2-3 Pap efficacy
study.5 The clinical costs included vaccine doses two and three, and office visits. The cost of initial
doses was excluded because it was a requirement for inclusion in the 1-2-3 Pap program.5 Office
visit costs were estimated using the percentage of Kentucky adults with private and Medicaid
insurance coverage, the Medicaid physician fee for outpatient services in Kentucky, and the
Medicaid-to-private-health-insurance conversion rate (Appendix).
In the adaptation scenario, laptop costs and community health nurse time were excluded because the
video would be shared and recommended to women while receiving their initial HPV vaccine dose.
Further, the video is available on YouTube, making it easy to share via other social media platforms
such as Facebook.
Total Cost. From a provider perspective, the total 1-2-3 Pap efficacy study cost was calculated as
the sum of the direct cost. The total 1-2-3 Pap adaptation cost would only include the clinical costs.
Total cost per series completed was estimated. Sensitivity analysis was used to estimate the costs if
the intervention would be 75% and 50% as effective in adaptation scenario compared to the efficacy
study.
RESULTS
The adaptation scenario population had 5930 eligible women aged 18 through 26 years. Among
these, assuming the same effectiveness as in the efficacy study, the estimated doses administered
were: 1346 initial, 587 adherence, and 412 completion doses.
1-2-3 Pap Efficacy Study Cost. The total 1-2-3 Pap efficacy study cost was $115,655.00 or $890
per series completed (n=130). Table 1.
Table 1: 1-2-3 Pap efficacy study costs per number of 3-dose HPV vaccine series completion, among
women aged 18–26 years who watched the video, in rural Kentucky
Cost/Unit ($)
(A)
Trial Participant Incentives
Gift Cards
Food - Used to Recruit Participants
Video Creation
Studio, Editing, and Production Services
Local Talent Fees

N of Units
(B)

Total Cost ($)
(C = A x B)

26

344 Cards

8,944

5

350 Servings

1,750

27,428

1 Production

27,428

67

6 Actors

Video Dissemination
Community Health Nurse

48

211 Nurses

10,128

Laptops (1/4 value)

278

4 Laptops

1,112

Clinical
Adherence Dose (Dose 2)

137

229 Doses

31,373

137

130 Doses

17,810

Office Visit - Medicaid

39

122 Visits

4,760

Office Visit - Private Insurance

52

230 Visits

Completion Dose (Dose 3)

Total Intervention Cost
Intervention Cost per Completed Series
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1-2-3 Pap Adaptation Cost. The estimated total cost of the adaptation scenario was $160,280, or
$389 per series completed (n = 412). Table 2.
Table 2: Hypothetical adaptation costs per number of 3-dose HPV vaccine series completion, among
women aged 18–26 years who watched the video, in rural Kentucky
Estimated Adaptation Cost (N = 1346)
100%
Effective a
Total Cost
($)
(C = A x B)

N of
Units
(B)

75%
Effective b
Total Cost
($)
(C = A x B)

N of
Units
(B)

50%
Effective c
Total Cost
($)
(C = A x B)

Cost/Unit
($)
(A)

N of
Units
(B)

137

587

80,419

381

52,186

175

23,972

137

412

56,444

267

36,512

121

16,596

20

340

6,793

220

4,402

101

2,014

Office Visit: Private
26
639
16,623
414
10,773
Insurance
Total Intervention Cost
160,280
103,873
Intervention Cost per
389
390
Completed Series
a. Total cost, assuming the adaptation is 100% as effective as the efficacy study
b. Total cost, assuming the adaptation is 75% as effective as the efficacy study
c. Total cost, assuming the adaptation is 50% as effective as the efficacy study

190

4,927

Clinical
Adherence Dose
(Dose 2)
Completion Dose
(Dose 3)
Office Visit: Medicaid

47,509
392

IMPLICATIONS
This analysis provides practitioners and decision makers with objective measures of the costs of
implementing 1-2-3 Pap in a larger population. The results supported the hypothesis that 1-2-3 Pap
implementation cost would decrease as it is offered to more people. Assuming the same success rate
as in the efficacy study, the adaptation scenario would cover 1000 additional women aged 18
through 26 years (344 in efficacy study; 1346 in adaptation scenario), and almost three times as many
completed series (130 in efficacy study; 412 in adaptation scenario) as in the original 1-2-3 Pap
efficacy study. 1-2-3 Pap’s total cost would decrease from $890 to $389 per women completing three
doses. Considering that the annual cost of cervical cancer screening and treatment ranges from
$30,775 to $52,731 per case (2010 USD),1 the estimated $890 investment per completed series might
be worthwhile. Findings likely translate to other rural areas, because local actors and community
members were used in the video to ensure cultural relevancies.
The next analytical steps are implementation cost estimations for a large urban county and the state
of Kentucky, and a cost-effectiveness analysis (CEA). The CEA will provide insight into
implementation costs and benefits such as healthcare costs avoided from preventing cervical cancer.
The 1-2-3 Pap efficacy study showed that women who watched the video were 2.44 times more
likely to complete the series than those who did not. However, initiation rates remain low among
this target population, and increased initiation remains a priority.4,5
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SUMMARY BOX
What is already known about this topic? The 1-2-3 Pap intervention is an informational and
instructional video created and tested to increase HPV vaccination completion rates among women aged
18 through 26 years residing in Appalachian Kentucky who had already received an initiation dose.
Women randomized to watch the 1-2-3 Pap video in addition to the standard of care (an educational
pamphlet and telephone reminder calls for doses 2 and 3) were 2.44 times more likely to complete the
HPV vaccine series than those in the standard-of-care-only group.
What is added by this report? Intervention estimated costs are critical to understanding the full scope of
available evidence. This study adds economic evidence of the effectiveness of the 1-2-3 Pap video.
What are the implications for public health practice, policy, and research? Determination of the
costs of implementing 1-2-3 Pap is vital for program expansion. This study provides practitioners and
decision makers with objective measures for scalability. The results supported the hypothesis that 1-2-3
Pap implementation cost would decrease as it is offered to more people. Findings likely translate to other
rural areas, because local actors and community members were used in the video to ensure cultural
relevancies.
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APPENDIX
Items

Data Sources

Studio, editing, and
production services
Local talent fees

University of Kentucky Rural Cancer Prevention Center

Laptop

University of Kentucky Rural Cancer Prevention Center purchased four laptop computers
for the efficacy study. Only a fourth of the value was applied to the intervention
implementation cost estimation, based on the assumption that the laptops were used for
other efficacy study related activities.
University of Kentucky Rural Cancer Prevention Center
CDC’s HPV Vaccine Information for Young Women (fact sheet)
(http://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-young-women.htm)
Estimated using the outpatient Medicaid reimbursement physician fee in Kentucky - $39
per visit (http://www.chfs.ky.gov/dms/fee.htm)
Estimated using the average private insurance coverage (64%) and Medicaid rates (34%)
for Kentucky (http://kff.org/other/state-indicator/adults-19-64/) and the Medicaid to
private insurance coverage rate (Private insurance coverage = 0.75 * Medicaid rate) (Ku
L. Medical and dental care utilization and expenditures under Medicaid and private health
insurance, 2009 [http://mcr.sagepub.com/content/66/4/456.refs])

Community health nurse
HPV vaccine dose cost
Office visit, Medicaid
Office visit, private
insurance

University of Kentucky Rural Cancer Prevention Center
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